Advanced pancreatic carcinoma showing a complete response to arterial infusion chemotherapy

We report a patient with advanced carcinoma of the pancreatic body and tail with multiple liver metastases who showed a complete response to hepatic and splenic arterial infusion chemotherapy (HSAIC) with gemcitabine and 5-fluorouracil, following transcatheter peripancreatic arterial embolization (T...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2004-06, Vol.9 (3), p.197-201
Main Authors: Homma, Hisato, Akiyama, Takehide, Mezawa, Shinichi, Doi, Tadashi, Takanashi, Kunihiro, Machida, Takuro, Murakami, Ken, Katsuki, Shinichi, Sato, Tsutomu, Hirata, Kenichiro
Format: Article
Language:English
Subjects:
Adenocarcinoma - blood supply
Adenocarcinoma - mortality
Adenocarcinoma - pathology
Adenocarcinoma - therapy
Adult
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Chemoembolization, Therapeutic
Chemotherapy
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Drug therapy
Fluorouracil - administration & dosage
Humans
Infusions, Intra-Arterial
Liver Neoplasms - blood supply
Liver Neoplasms - secondary
Male
Metastasis
Pancreas
Pancreatic cancer
Pancreatic Neoplasms - blood supply
Pancreatic Neoplasms - mortality
Pancreatic Neoplasms - pathology
Pancreatic Neoplasms - therapy
Veins & arteries
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report a patient with advanced carcinoma of the pancreatic body and tail with multiple liver metastases who showed a complete response to hepatic and splenic arterial infusion chemotherapy (HSAIC) with gemcitabine and 5-fluorouracil, following transcatheter peripancreatic arterial embolization (TPPAE) and partial splenic embolization (PSE). Nonresectable advanced pancreatic carcinoma tends to have a low response to medical treatment, with the median survival time being 6 months or less for stage IV cases. We disclose herein that the median survival time of patients receiving HSAIC after TPPAE is more than three times longer than the survival time attained with conventional treatments. However, in patients with advanced carcinoma of the pancreatic tail, for which TTPAE is not applicable, survival times remain low. Thus, in the patient described here, we also performed embolization of the left gastric and short gastric arteries as well as PSE to increase the flow within the great pancreatic and caudal pancreatic arteries via the splenic artery, and gemcitabine and 5-fluorouracil were administered via the splenic artery. As a result of these procedures, marked reduction in the advanced carcinoma of the pancreatic body and tail and of liver metastases was attained.
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-004-0388-2